Zentalis Pharmaceuticals, Inc.
NGM: ZNTLLive Quote
📈 ZcoreAI Score
Our AI model analyzes Zentalis Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ZNTL Z-Score →About Zentalis Pharmaceuticals, Inc.
Healthcare
Biotechnology
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Zentalis Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -49.5%, which indicates that capital utilization is currently under pressure.
At a current price of $6.61, ZNTL currently trades near the top of its 52-week range (94%) (Range: $1.13 - $6.95).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$468.85M
Trailing P/E
--
Forward P/E
-4.25
Beta (5Y)
1.66
52W High
$6.95
52W Low
$1.13
Avg Volume
1.68M
Day High
Day Low